文献速递肿瘤 PET/CT核素与放射性配体治疗

具有改良药代动力学特性的PSMA靶向PET示踪剂的开发与首次人体研究

Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-04-29

研究基于[68Ga]Ga-PSMA-617开发了四种新型68Ga标记示踪剂,在LNCaP荷瘤B-NSG雄性小鼠中进行PET显像与生物分布实验,其中[68Ga]Ga-TWS02的肿瘤/肾脏比值(0.93)和肿瘤/肌肉比值(107.62)高于[68Ga]Ga-PSMA-617和[68Ga]Ga-PSMA-11。首次人体研究显示[68Ga]Ga-TWS02可有效检出前列腺癌原发及转移病灶,泌尿系统蓄积较低。

要点

  • 四种示踪剂放射化学纯度均>95%,摩尔活度20.0-25.5 GBq/μmol。
  • [68Ga]Ga-TWS02在注射后1.5小时PET显像中肿瘤显示清晰。
  • 首次人体研究中[68Ga]Ga-TWS02可检出前列腺癌原发和转移病灶。

核心结论

  • 将喹啉基团、苯丙氨酸和癸酸引入不同示踪剂可调节PSMA在体内的结合亲和力和药代动力学。
  • [68Ga]Ga-TWS02对PSMA具有高结合亲和力、优异的药代动力学特性,可清晰显像前列腺癌相关病灶,是临床诊断前列腺癌有前景的放射性示踪剂。
  • 含螯合剂DOTA的TWS02还可标记177Lu和225Ac,可用于前列腺癌治疗且无明显副作用。

研究设计与样本

  • 研究基于[68Ga]Ga-PSMA-617开发了一系列新型68Ga标记示踪剂。
  • 体外实验采用饱和结合实验和竞争结合实验测定示踪剂与LNCaP细胞的结合亲和力。
  • 体内代谢研究、PET显像和生物分布实验在LNCaP荷瘤B-NSG雄性小鼠中进行。
  • 选择最有前景的示踪剂进行首次人体研究,临床评估于2021年10月30日在https://www.chictr.org.cn/注册(编号ChiCTR2100052545)。

主要发现

  • 合成了四种放射性示踪剂,放射化学纯度(RCP)>95%,摩尔活度范围为20.0-25.5 GBq/μmol。
  • TWS01和TWS02对PSMA的结合亲和力(Ki)在低纳摩尔范围(<10 nM),TWS03和TWS04的Ki>20 nM(TWS03为59.42 nM,TWS04为37.14 nM)。
  • 除[68Ga]Ga-TWS03外,所有放射性示踪剂在体内均表现出高稳定性。
  • 微小PET/CT显像和生物分布分析显示,[68Ga]Ga-TWS02在注射后1.5小时PET图像中可清晰显示肿瘤,肿瘤/肾脏比值(T/K)为0.93、肿瘤/肌肉比值(T/M)为107.62,而[68Ga]Ga-PSMA-617的T/K为0.39、T/M为15.01,[68Ga]Ga-PSMA-11的T/K为0.15、T/M为24.00。
  • 首次人体研究中,[68Ga]Ga-TWS02有效检出前列腺癌相关病灶(包括原发和转移病灶),泌尿系统蓄积较低。

临床怎么用

  • 首次人体研究提示[68Ga]Ga-TWS02可能应用于膀胱侵犯的检测,并减少对泌尿系统的辐射毒性。
  • 作者认为[68Ga]Ga-TWS02是临床诊断前列腺癌有前景的放射性示踪剂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A series of new 68Ga-labeled tracers based on [68Ga]Ga-PSMA-617 were developed to augment the tumor-to-kidney ratio and reduce the activity accumulation in bladder, ultimately minimize radiation toxicity to the urinary system. METHODS: We introduced quinoline group, phenylalanine and decanoic acid into different tracers to enhance their lipophilicity, strategically limiting their metabolic pathway through the urinary system. Their binding affinity onto LNCaP cells was determined through in vitro saturation assays and competition binding assays. In vivo metabolic study, PET imaging and biodistribution experiment were performed in LNCaP tumor-bearing B-NSG male mice. The most promising tracer was selected for first-in-human study. RESULTS: Four radiotracers were synthesized with radiochemical purity (RCP) > 95% and molar activity in a range of 20.0-25.5 GBq/μmol. The binding affinities (Ki) of TWS01, TWS02 to PSMA were in the low nanomolar range (< 10 nM), while TWS03 and TWS04 exhibited binding affinities with Ki > 20 nM (59.42 nM for TWS03 and 37.14 nM for TWS04). All radiotracers exhibited high stability in vivo except [68Ga]Ga-TWS03. Micro PET/CT imaging and biodistribution analysis revealed that [68Ga]Ga-TWS02 enabled clear tumor visualization in PET images at 1.5 h post-injection, with higher tumor-to-kidney ratio (T/K, 0.93) and tumor-to-muscle ratio (T/M, 107.62) compared with [68Ga]Ga-PSMA-617 (T/K: 0.39, T/M: 15.01) and [68Ga]Ga-PSMA-11 (T/K: 0.15, T/M: 24.00). In first-in-human study, [68Ga]Ga-TWS02 effectively detected PCa-associated lesions including primary and metastatic lesions, with lower accumulation in urinary system, suggesting that [68Ga]Ga-TWS02 might be applied in the detection of bladder invasion, with minimized radiation toxicity to the urinary system. CONCLUSION: Introduction of quinoline group, phenylalanine and decanoic acid into different tracers can modulate the binding affinity and pharmacokinetics of PSMA in vivo. [68Ga]Ga-TWS02 showed high binding affinity to PSMA, excellent pharmacokinetic properties and clear imaging of PCa-associated lesions, making it a promising radiotracer for the clinical diagnosis of PCa. Moreover, TWS02 with a chelator DOTA could also label 177Lu and 225Ac, which could be used for PCa treatment without significant side effects. TRIAL REGISTRATION: The clinical evaluation of this study was registered On October 30, 2021 at https://www.chictr.org.cn/ (No: ChiCTR2100052545).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hou H, Pan Y, Wang Y, et al. Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties. Eur J Nucl Med Mol Imaging. 2024. PMID: 38683349. doi:10.1007/s00259-024-06726-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。